A compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, a method for inhibiting a disease associated with estrogen deprivation, a method for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen, and the use of a compound.

摘要

"COMPOUND OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING A DISEASE ASSOCIATED, METHOD FOR INHIBITING A DISEASE ASSOCIATED WITH A PHYSIOGENOUS RESPONSE, ENHANCED RESPONSE The present invention provides a compound of formula (I) wherein R1 is -H, -OH, -O (C1-C4-alkyl), -OCOC-6-H5, -OCO (C 1 -C 6 -alkyl), or -OSO -2 C (C 2 -C 6 alkyl); R 4 O 4, R 2 and R 3 are each independently -H, -OH, -O (C 1 -C 4 -alkyl), -OCOC 6 -H-5 -OCO (C 1 -C 6 alkyl), -OSO 2 C (C 2 -C 6 alkyl) or halo; R 4 R 4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholine, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is S- or -HC = CH-; and Y is O-, -S-, -NH-, -NMe-, or, -CH 2 -; or a pharmaceutically acceptable salt thereof; their pharmaceutical compositions, optionally in combination with estrogen and progestin; methods of inhibiting an illness associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.